Imcare Biotech Overview
- Year Founded
-
2011
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$153K
- Investors
-
1
Imcare Biotech General Information
Description
Developer of diagnostic and pharmaceutical products designed to be used for the treatment of liver-related illnesses. The company develops diagnostic biomarkers and developmental drugs for liver diseases such as hepatocellular carcinoma and intrahepatic cholangiocarcinoma, enabling doctors to diagnose and treat liver-related illnesses.
Contact Information
Website
www.imcarebiotech.comCorporate Office
- 3805 Old Easton Road
- Doylestown, PA 18902
- United States
Corporate Office
- 3805 Old Easton Road
- Doylestown, PA 18902
- United States
Imcare Biotech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Later Stage VC | 14-Jul-2023 | $153K | Completed | Generating Revenue | ||
| 5. Later Stage VC | 13-Apr-2022 | Completed | Generating Revenue | |||
| 4. Later Stage VC | 27-Jul-2021 | Completed | Generating Revenue | |||
| 3. Angel (individual) | 12-Mar-2020 | Completed | Generating Revenue | |||
| 2. Grant | 01-Apr-2015 | $2.24M | Completed | Startup | ||
| 1. Grant | 01-Sep-2012 | $1.42M | Completed | Startup |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Imcare Biotech Patents
Imcare Biotech Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2026012693-A | Epitope of anti-serine protease inhibitor kazal (spik) antibody | Pending | 11-Sep-2019 | ||
| CA-3150538-A1 | Epitopes of anti-serine protease inhibitor kazal (spik) antibodies | Pending | 11-Sep-2019 | ||
| EP-4028132-A1 | Epitopes of anti-serine protease inhibitor kazal (spik) antibodies | Pending | 11-Sep-2019 | ||
| US-20240043512-A1 | Epitopes of anti-serine protease inhibitor kazal (spik) antibodies | Inactive | 11-Sep-2019 | ||
| WO-2021050217-A1 | Epitopes of anti-serine protease inhibitor kazal (spik) antibodies | Inactive | 11-Sep-2019 | C07K16/38 |
Imcare Biotech Signals
Imcare Biotech Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| National Science Foundation Innovation Corps Program | Accelerator/Incubator |
Imcare Biotech FAQs
-
When was Imcare Biotech founded?
Imcare Biotech was founded in 2011.
-
Where is Imcare Biotech headquartered?
Imcare Biotech is headquartered in Doylestown, PA.
-
What is the size of Imcare Biotech?
Imcare Biotech has 10 total employees.
-
What industry is Imcare Biotech in?
Imcare Biotech’s primary industry is Drug Discovery.
-
Is Imcare Biotech a private or public company?
Imcare Biotech is a Private company.
-
What is Imcare Biotech’s current revenue?
The current revenue for Imcare Biotech is .
-
How much funding has Imcare Biotech raised over time?
Imcare Biotech has raised $4.26M.
-
Who are Imcare Biotech’s investors?
National Science Foundation Innovation Corps Program has invested in Imcare Biotech.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process